Blueprint Medicines Corporation

This study follows 80 adults in Germany with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. Researchers will track how well avapritinib works in real-world settings over up to 24 months, focusing on quality of life and symptom control…

This study is for people with systemic mastocytosis who are already taking avapritinib and benefiting from it. It aims to track long-term safety by monitoring serious side effects. About 60 participants will continue their current treatment and be followed over time. No new drug …

This study tests an experimental drug called BLU-808 for people with chronic hives (either triggered by heat/cold/pressure or happening without a clear cause) that don't get better with standard allergy pills. The drug works by blocking a protein called KIT, which may calm the im…

This study tests a new drug called elenestinib (BLU-263) for people with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. About 534 adults will receive either the study drug or a placebo, plus standard symptom therapy. The goal is to se…

This study is screening up to 450 people who may have clonal mast cell disease, a condition where immune cells become overactive. The goal is to find how many carry a specific genetic change called KIT D816V using sensitive blood tests. Participants provide blood samples, and the…

This study watches how indolent systemic mastocytosis (ISM) affects people in everyday life. Researchers will collect information on symptoms, treatments, and quality of life from 150 adults. No new drugs are tested; the goal is to learn more about the disease and how it is manag…